Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

US Patent 10925876 · Granted Feb 23, 2021

Estimated economic value: $566,829,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Carbamate and urea compounds as multikinase inhibitors2022
Cyclic compounds as immunomodulating agents2021
Macrocyclic compounds as TRK kinase inhibitors and uses thereof2021
Insulin dimer-incretin conjugates2021
Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors2021
Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors2021
Substituted quinolizine derivatives useful as HIV integrase inhibitors2020
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators2020
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators2020
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators2020
Soluble guanylate cyclase stimulators2019
Soluble guanylate cyclase stimulators2019